Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK105 Plus Anlotinib and Albumin Paclitaxel in Advanced TNBC
NCT05244993Phase 2Unknown
- Sponsor
- Liaoning Medical Center
- Start
- Jul 2022
- Primary completion
- Mar 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of penpulimab, anlotinib in triple-negative breast cancer (TNBC), sponsored by Liaoning Medical Center. Status: unknown.
02
Drugs
penpulimabanlotinib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05244993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05244993.